Jamal Ibdah, MD
Enriched profileProfessor of Medical Pharmacology and Physiology; Director, Gastroenterology and Hepatology Fellowship Programs · University of Missouri Columbia School of Medicine
Jamal Ibdah is Professor of Medical Pharmacology and Physiology; Director, Gastroenterology and Hepatology Fellowship Programs at University of Missouri Columbia School of Medicine. OpenAlex indexes 271 publications with 9,725 citations (h-index 53); ClinicalTrials.gov lists 3 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Gastroenterology profiles in the findmyKOL directory.
Data verified 11 Oct 2026
Overview
Updated 15 Oct 2026
Jamal Ibdah, M.D., is Professor of Medical Pharmacology and Physiology at University of Missouri Columbia School of Medicine. The public record shows 271 publications with 9,725 citations (h-index 53), centered on Liver Disease Diagnosis and Treatment, Mitochondrial Function and Pathology, Metabolism and Genetic Disorders. It also documents an investigator role on 3 registered clinical trials, 6 NIH-funded awards (2005–2025).
- Most recent indexed publication: 2026 · International journal of molecular sciences
- Top research focus: Liver Disease Diagnosis and Treatment
- 3 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 15 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 112.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 15 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans
Sponsor: VA Office of Research and Development
- The Liver Health Study for Patients with NAFLD
Sponsor: University of Missouri-Columbia
- Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease
Sponsor: University of Missouri-Columbia
Industry payments
No payments involving this person were reported to CMS in program years 2021–2024. Why? →
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
95.4%Osmotic Laxative95.4%Gavilyte-G55%Peg-3350 And Electrolytes28%Gavilyte-C13%Golytely3%Part D≥279 patientsBlood & clotting
4.6%Solutions for parenteral nutrition4.6%Peg 3350-Electrolyte100%Part D≥24 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 15 Oct 2026
6 NIH research awards on record, funded 2005–2025 per NIH RePORTER. The latest:
- Low Dose Thyroid Hormone, Mitochondrial Fatty Acid Oxidation, and Treatment of Nonalcoholic Steatohepatitis (NASH)
Harry S. Truman Memorial Va Hospital
FY2025I01CX002436 - Low Dose Thyroid Hormone, Mitochondrial Fatty Acid Oxidation, and Treatment of Nonalcoholic Steatohepatitis (NASH)
Harry S. Truman Memorial Va Hospital
FY2024I01CX002436 - Role of non-genomic regulation of mitochondrial trifunctional protein in NAFLD
Harry S. Truman Memorial Va Hospital
FY2023I01BX004710
Congress activity
Updated 15 Oct 2026
4 congress contributions (2020–2025) across ADA per OpenAlex. The most recent:
- 285-OR: Lifestyle Treatment-Induced Improvements in Nonalcoholic Steatohepatitis (NASH)
ADA Scientific Sessions
ADA2021Co-authorOral - 310-OR: Role of Glucose Flux to Elevate Hepatic Lipogenesis in Biopsy-Proven NASH
ADA Scientific Sessions
ADA2020Co-authorOral
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 15 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Exercise-Induced Hepatic Mitochondrial Reprogramming Across Muscle-Gut-Thyroid Axes in MASLD/MASH.
International journal of molecular sciences
Review2026 - Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease.
International journal of molecular sciences
Review2022
Most-cited works
by citation count (OpenAlex)- 01A Fetal Fatty-Acid Oxidation Disorder as a Cause of Liver Disease in Pregnant WomenArticle500 citations1999
- 02
- 03
- 04Nonalcoholic fatty liver disease and mitochondrial dysfunctionArticle370 citations2008
- 05Role of Mitochondria in Nonalcoholic Fatty Liver DiseaseArticle367 citations2014
Network
Updated 15 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 15 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Jordan
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →muhealth.org ↗ - Board certified
American Board of Internal Medicine, Gastroenterology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →muhealth.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →muhealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →muhealth.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →muhealth.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →muhealth.org ↗
Media & interviews
press, podcasts and appearances- Becker's ASC Review feature: GI physician leader to know
Dr. Jamal Ibdah
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →beckersasc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH